Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 11/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.39 |
| ▸ | RXRA | P19793 | 2/20 | 0.36 |
| ▸ | RXRB | P28702 | 2/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GRN | P28799 | 1/20 | 0.35 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.35 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15907118 | 0.86 | MAPK13 (0.46) | MAPK13RAF1KDM4EMEN1KMT2A | |
| SCHEMBL15907129 | 0.84 | MAPK13 (0.47) | MAPK13RAF1KDM4EJMJD6 | |
| SCHEMBL10378912 | 0.79 | KDM4E (0.40) | HCAR3KDM4EMEN1KMT2AJMJD6 | |
| SCHEMBL17229830 | 0.75 | MAPK13 (0.49) | MAPK13HCAR3JMJD6MAPK14 | |
| SCHEMBL15900088 | 0.75 | DNMT1 (0.45) | HCAR3RXRARXRBKDM4EMEN1 | |
| SCHEMBL22958082 | 0.75 | NR4A1 (0.42) | HCAR3KDM4EMEN1KMT2AJMJD6 | |
| SCHEMBL15907119 | 0.75 | DNMT1 (0.56) | MAPK13RAF1KDM4EMEN1KMT2A | |
| SCHEMBL16456007 | 0.75 | MAPK13 (0.40) | MAPK13RAF1MEN1KMT2AMAPK14 | |
| SCHEMBL20053791 | 0.74 | HCAR3 (0.35) | MAPK13HCAR3KDM4EMEN1KMT2A | |
| SCHEMBL3622319 | 0.73 | MAPK13 (0.39) | MAPK13RAF1MEN1KMT2AMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522910-B2 | Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon | Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) | 2016-12-20 | — | — | US | disclosed |
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | ABL1, ABL2, MAP3K6 | MAPK13 59/4885RAF1 84/4885HCAR3 4451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.